CompletedNot Applicable

Retrospective Study of High Dose Follitropin Delta in a Mixed Protocol With Human Chorionic Gonadotropin

Canada118 participantsStarted 2023-05-20

Plain-language summary

Follitropin delta is a rFSH, uniquely expressed in a human fetal retinal cell line, which owing to differences in glycosylation profile has a lower clearance and induces a higher ovarian response in humans than existing rFSH preparations when administered at equal doses of biological activity. A noninferiority clinical trial (ESTHER-1) in which individualized dosage of follitropin delta according to each patient's profile (AMH and weight) was compared to conventional follitropin alfa dosing for IVF have demonstrated that an individualized follitropin delta dosing is noninferior to conventional follitropin alfa with respect to ongoing pregnancy rate, ongoing implantation rate, and also live births, with a concomitant reduction in iatrogenic complications, including OHSS

Who can participate

Age range18 Years – 42 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Women 18 to 42 years of age undergoing IVF/ICSI cycle * IVF antagonist protocol * Regular menstrual cycles of 24-35 days * Presence of both ovaries Exclusion Criteria: * Endometriosis stage III/IV * History of recurrent miscarriages, defined as ≥ 3 consecutive losses * Women undergoing ovarian stimulation for oncologic or elective fertility preservation * Women participating in any other research project * Hypersensitivity to follitropin delta and/or human chorionic gonadotropin * Use of Growth Hormone (GH) during the stimulation cycle

What they're measuring

Number of good quality blastocysts

Timeframe: Up to 6 day

Trial details

NCT IDNCT05873725

SponsorClinique Ovo

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2023-09-30

View on ClinicalTrials.gov More IVF trials